Mabiotech : Système diagnostique moléculaire DxN VERIS - BECKMAN COULTER

Système diagnostique moléculaire DxN VERIS - BECKMAN COULTER

Nous contacter
/ / / / /
Système diagnostique moléculaire DxN VERIS - BECKMAN COULTER

DxN VERIS SYSTEM
FROM SAMPLE TO RESULTS IN 3 SIMPLE STEPS

 

THE VERIS ASSAYS*

The VERIS Assays use real-time PCR for accurate and precise quantitative detection of both RNA and DNA targets. The assays are developed in compliance with CLSI guidelines and ISO standards, and calibrated to WHO standards. Each quantitative test offers a broad measuring interval and high sensitivity to ensure you get the answer you need.

The internal process control which follows the entire automated workflow on the DxN VERIS System*, combined with the system’s contamination control design, ensures you can be confident in the result.

Single sample random access offers workflow flexibility and automation benefits which means you can run the test you want when you want to better serve the clinician and patient. Faster, accurate answers ensure better treatment decisions.

 

VERIS ASSAYS AVAILABLE NOW!

The first assays available for DxN VERIS include a full family of viral load CE mark assays for Cytomegalovirus, Hepatitis B, Hepatitis C, and HIV-1. These assays are crucial to managing disease treatment on patients affected by these conditions. These four assays are currently available in Europe and other selected countries only.

 

VERIS CMV ASSAY

THE VERIS HUMAN CYTOMEGALOVIRUS (CMV) ASSAY* 

The VERIS CMV Assay is an in vitro nucleic acid amplification real-time PCR assay for the quantitative determination of CMV DNA in human plasma using the DxN VERIS Molecular Diagnostic System*. The assay relies on the TaqMan®detection method and is intended for use in conjunction with clinical presentation and other laboratory findings as an aid in monitoring CMV viral load in individuals at risk of CMV complications, such as immunocompromised individuals or very young babies.

This test is not intended for use as a screening test for the presence of CMV in blood or blood products or as a diagnostic test to confirm the presence of CMV infection.

 

 

VERIS HBV ASSAY

THE VERIS HEPATITIS B VIRUS (HBV) ASSAY*

The VERIS HBV Assay is an in vitro PCR assay for the quantitative determination of HBV DNA in human K2EDTA plasma and serum using the DxN VERIS Molecular Diagnostic System*. The assay has been validated to provide quantitative results from specimens containing HBV genotypes A through H, and uses the TaqMan®detection method.

The assay is intended for use as an aid in the management of HBV‐infected individuals undergoing antiviral therapy in conjunction with clinical presentation and other laboratory markers. This test is not intended for use as a screening test for the presence of HBV in blood or blood products or as a diagnostic test to confirm the presence of HBV infection.

 

 

VERIS HCV ASSAY

THE VERIS HEPATITIS C VIRUS (HCV) ASSAY*

The VERIS Hepatitis C Virus (HCV) Assay is an in vitro PCR reaction assay for the quantitative determination of HCV RNA in human K2EDTA plasma using the DxN VERIS Molecular Diagnostics System*. The assay has been validated to provide quantitative results from specimens containing HCV genotypes 1 through 6 and are based on the TaqMan® detection method.

The VERIS HCV Assay is intended for use on human K2EDTA plasma as an aid in the management of HCV-infected individuals undergoing antiviral therapy in conjunction with clinical presentation and other laboratory markers. The assay measures HCV RNA levels at baseline and during treatment and can be used to aid in assessing response to treatment. This test is not intended for use as a screening test for the presence of HCV in blood or blood products or as a diagnostic test to confirm the presence of HCV infection.

 

HIV-1 ASSAY

THE VERIS HUMAN IMMUNODEFICIENCY VIRUS-1 (HIV-1) ASSAY*

The VERIS Human Immunodeficiency Virus- 1 (HIV-1) Assay is an in vitro real-time PCR assay for the quantitative determination of HIV-1 RNA in human plasma using the DxN VERIS Molecular Diagnostics System*. The assay has been validated to provide quantitative results from specimens containing HIV-1 group M subtypes, group O, and group N.

The assay is intended for use on human (K2EDTA) plasma as an aid in the management of HIV-1 infected individuals undergoing antiviral therapy in conjunction with clinical presentation and other laboratory markers. The assay measures HIV-1 RNA levels at baseline and during treatment, and can be used to aid in assessing response to treatment. This test is not intended for use as a screening test for the presence of HIV-1 in blood or blood products or as a diagnostic test to confirm the presence of HIV-1 infection.